O’Brien Figure 2.
O’Brien Figure 2. Estimated overall progression-free survival at 30 months in imatinib-treated patients. IRIS/0106 trial.

Estimated overall progression-free survival at 30 months in imatinib-treated patients. IRIS/0106 trial.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal